Balyasny Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Balyasny Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$1.66M	–	2742
2025 Q1	$1.66M	Buy	+100,000	New	+$1.82M	﹤0.01%	1789
2024 Q3	–	Sell	-200,000	Closed	-$3.25M	–	2684
2024 Q2	$3.25M	Buy	+200,000	New	+$3.23M	0.01%	1352
2024 Q1	–	Sell	-100,000	Closed	-$3.13M	–	2557
2023 Q4	$3.13M	Buy	+100,000	New	+$2.39M	0.01%	1301
2020 Q4	–	Sell	-150,000	Closed	-$6.19M	–	1268
2020 Q3	$6.19M	Buy	+150,000	New	+$6.48M	0.05%	534
2018 Q4	–	Sell	-55,000	Closed	-$831K	–	1348
2018 Q3	$831K	Buy	+55,000	New	+$865K	﹤0.01%	1234
2017 Q3	–	Sell	-150,000	Closed	-$4.18M	–	1836
2017 Q2	$4.18M	Buy	+150,000	New	+$4.47M	0.02%	791

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Balyasny Asset Management's ACAD Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 312,982 shares worth $6.97M. The stake represents 0.01% of the portfolio and ranks #1206 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ACAD as recently as Q4 2024.

Balyasny Asset Management first reported a position in ACAD in Q4 2016 and has held it in 18 quarters since. The position peaked at $26.1M in Q3 2018. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Balyasny Asset Management held 312,982 shares of Acadia Pharmaceuticals worth $6.97M as of Q1 2026.
Acadia Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
Acadia Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1206 holding.
Balyasny Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 18 quarters since.
Balyasny Asset Management's Acadia Pharmaceuticals position peaked at $26.1M in Q3 2018.
342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.